公开(公告)号：US20220168349A1

公开(公告)日：2022-06-02

申请号：US17438386

申请日：2020-02-27

申请人： NANTCELL, INC. ,  NantBio, Inc. ,  NantKwest, Inc.

发明人： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Hans G. Klingemann

IPC分类号： A61K35/17 ,  C07K14/54 ,  C12N5/0783 ,  A61P35/00

摘要： Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

公开(公告)号：US20220016214A1

公开(公告)日：2022-01-20

申请号：US17475783

申请日：2021-09-15

申请人： NantCell, Inc.

发明人： Kayvan Niazi ,  Jeffrey Safrit ,  John H. Lee

IPC分类号： A61K38/20 ,  A61K31/167 ,  A61K31/4045 ,  A61K31/192 ,  A61K31/4406 ,  C07K16/10 ,  A61K31/215 ,  A61K35/17 ,  C07K14/735 ,  A61K39/12 ,  A61K31/506

摘要： HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.

公开(公告)号：US20200283531A1

公开(公告)日：2020-09-10

申请号：US16753330

申请日：2018-10-04

申请人： NantCell, Inc.

发明人： Kayvan Niazi ,  Marcos Sixto ,  Annie Shin ,  Phil Liu

IPC分类号： C07K16/28 ,  A61K35/17 ,  C12N5/0783 ,  A61K39/39 ,  A61K9/00

摘要： Compositions, methods and uses of genetically modified NK cells to elicit immune response against cells infected with microorganisms are presented. In some embodiments, NK cells can be genetically modified with a recombinant nucleic acid that includes a segment encoding an extracellular single-chain variant fragment that specifically binds a CD1-lipid antigen complex and another segment encoding an intracellular activation domain, and a linker between those segments. In other embodiments, the NK cells can be genetically modified with a recombinant nucleic acid that includes a segment encoding an a chain T cell receptor and a β chain T cell receptor, and another segment encoding at least a portion of CD3δ and at least a portion of CD3γ. The genetically modified NK cells can be administered to the patient infected with microorganism to trigger immune response specific to the cells infected with the microorganism.

公开(公告)号：US20190381141A1

公开(公告)日：2019-12-19

申请号：US16443560

申请日：2019-06-17

申请人： NANTCELL, INC.

发明人： Kayvan Niazi ,  Jeffrey Safrit ,  John H. Lee

IPC分类号： A61K38/20 ,  A61K31/167 ,  A61K31/4045 ,  A61K31/192 ,  A61K31/4406 ,  A61K31/506 ,  A61K31/215 ,  A61K35/17 ,  C07K14/735 ,  A61K39/12 ,  C07K16/10

摘要： HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.

公开(公告)号：US11573230B2

公开(公告)日：2023-02-07

申请号：US16964325

申请日：2019-01-25

申请人： NANTCELL, INC. ,  NANTBIO, INC.

发明人： Adrian E. Rice ,  Kayvan Niazi ,  Frank R. Jones

IPC分类号： C12Q1/70 ,  G01N33/569 ,  A61K39/00 ,  C12N15/86

摘要： Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.

公开(公告)号：US20220257660A1

公开(公告)日：2022-08-18

申请号：US17732190

申请日：2022-04-28

申请人： NantCell, Inc. ,  NantBio, Inc. ,  ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Hans G. Klingemann

IPC分类号： A61K35/17 ,  A61P35/00 ,  C12N5/0783 ,  C07K14/54

摘要： Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

公开(公告)号：US11221328B2

公开(公告)日：2022-01-11

申请号：US16491559

申请日：2018-03-07

申请人： NANTCELL, INC.

发明人： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Stephen Charles Benz ,  Laurent H. Boissel ,  Hans Klingemann ,  Barry J. Simon

IPC分类号： C12Q1/6886 ,  G01N33/50 ,  G16H50/30 ,  C12N5/0783

摘要： Detection of under-expression of selected genes in NK cells is used to confirm a hypoxic tumor microenvironment that is ordinarily suppressive with respect to ADCC and cytotoxic cell killing of NK cells. Most notably, while hypoxia is known to upregulate HIF-1α and genes under the control of HIF-1α, hypoxia in a tumor microenvironment led to under-expression of selected genes, including HIF-1α. Thus, gene expression analysis of certain genes on NK cells can be used to detect conditions in a tumor that would indicate use of haNK cells.

公开(公告)号：US20200331976A1

公开(公告)日：2020-10-22

申请号：US16753272

申请日：2018-10-04

申请人： NANTCELL, INC.

发明人： Patrick Soon-Shiong ,  Kayvan Niazi

IPC分类号： C07K14/47 ,  C07K14/74 ,  C12N15/86 ,  A61K48/00 ,  A61K39/00

摘要： Compositions, methods, and uses of recombinant nucleic acids to elicit Th1- or Th2-biased immune responses in an individual are presented. In some embodiments, the nucleic acid includes a first nucleic acid segment encoding a MHC-II trafficking signal and a second nucleic acid segment encoding a polytope peptide and a Th1-specific polarizing epitope or a Th2-specific polarizing epitope. Optionally, the Th1-specific polarizing epitope or the Th2-specific polarizing epitope is part of the polytope peptide. The recombinant nucleic acid can be inserted in a viral, bacterial, or yeast expression vector so that the recombinant protein encoded by the recombinant nucleic acid can be expressed in an antigen presenting cell of an individual to elicit Th1- or Th2-biased immune response in the individual.